The limited efficacy of immune checkpoint inhibitor treatment in triple-negative breast cancer
(TNBC) patients is attributed to sparse or unresponsive tumor-infiltrating lymphocytes, but …

The cytokine interleukin-6 (IL6) and its downstream effector STAT3 constitute a key oncogenic
pathway, which has been thought to be functionally connected to estrogen receptor α (ER) …

Male breast cancer (MBC) is rare and poorly characterized. Like the female counterpart, most
MBCs are hormonally driven, but relapse after hormonal treatment is also noted. The pan-…

Understanding initial changes that enable survival of tamoxifen-tolerant cells, as mediated
by NF-κB pathway, may translate into therapeutic interventions to prevent resistance and …

Androgen receptor (AR) drives prostate cancer (PCa) development and progression. AR
chromatin binding profiles are highly plastic and form recurrent programmatic changes that …

Background Invasive lobular carcinoma (ILC) accounts for 10–15% of primary breast cancers
and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic …

Estrogen Receptor 1 (ESR1; also known as ERα, encoded by ESR1 gene) is the main driver
and prime drug target in luminal breast cancer. ESR1 chromatin binding is extensively …

The magnitude and scope of intrinsic age-correlated and host endocrine age-correlated gene
expression in breast cancer is not well understood. From age-correlated gene expression …

The authors have withdrawn their manuscript whilst they perform additional experiments to
test some of their conclusions further. Despite repetitive attempts to reproduce the data …

Immune checkpoint inhibitor (ICI) treatment has thus far shown limited efficacy in triple-negative
breast cancer (TNBC) patients, presumably due to sparse or unresponsive tumor-…